Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.

However, although favouring psilocybin over escitalopram on secondary outcomes, the primary efficacy endpoint (self-reported Inventory of Depressive Symptomatology) did not reach statistical significance. 8 Given that a rapid decrease in symptom severity was observed in both intervention arms, it is possible that the psychological support and the low dose of psilocybin may have contributed significantly to the therapeutic effect.

also in 111,027 other papers